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combinations based on the breakpoint of MERO. The strains harboring K73R, S130G, and 
K234R had slightly elevated MERO-nacubactam MICs relative to wild type but did not 
have corresponding increases in MERO MICs. Strains with pBC SK-KPC2, K73R or S130G 
had 0.015 mg/L MERO MICs. The pBR322-K234R strain had a twofold lower MERO MIC 
than pBR322-KPC-2 (Figure 1C). The IC50 of cell extracts containing the K234R variant is 
781 µM, which is 12-fold higher than that for KPC-2 (66 µM) (Figure 1C). Extracts con-
taining the S130G variant were not inhibited by nacubactam (IC50 > 2.6 mM).
Conclusion. Meropenem-nacubactam is an effective β-lactam β-lactamase inhibitor 
combination for Enterobacteriaceae with KPC or OXA-48 β-lactamases. The single amino 
acid substitutions K73R, S130G, and K234R in KPC-2 affect the inactivation mechanism.
Disclosures. M. R. Jacobs, F. Hoffmann-La Roche Ltd.: Grant Investigator, Research 
grant. K. M. Papp-Wallace, F. Hoffmann-La Roche Ltd.: Grant Investigator, Research 
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Background. Klebsiella pneumoniae is a frequently multidrug-resistant organism 
with a high propensity to form biofilm. K. pneumoniae is the most common carbap-
enem-resistant Enterobacteriaceae (CRE), and labeled an urgent threat by the CDC. 
The relationship between K. pneumoniae biofilm formation and specific antimicrobial 
resistance patterns has not been well defined.
Methods. K. pneumoniae isolates (n = 139) were evaluated for antimicrobial resist-
ance and biofilm formation (CDC, Providence VA Med. Ctr., Rhode Island Hosp., BEI, and 
ATCC). Susceptibility was based predominantly on 2017 CLSI (Clinical and Laboratory 
Standards Institute) breakpoints. Isolates were categorized as multidrug-resistant (MDR: 
resistant to ≥ 1 antimicrobial in ≥ 3 out of 16 antimicrobial categories) or extensively 
drug-resistant (XDR: resistant to ≥ 1 antimicrobial in all but ≤ 2 out of 16 antimicro-
bial categories) based on expert consensus criteria for Enterobacteriaceae (European CDC 
(ECDC)/CDC, 2012). We collapsed antimicrobial categories described by the ECDC/
CDC consensus group into nine categories: penicillins, cephalosporins, monobactam, 
carbapenems, protein synthesis inhibitors, fluoroquinolones, folate pathway inhibitors, 
fosfomycin, and colistin. Biofilm formation was assessed using a modified crystal violet 
method (OD570) and defined by tertile cut-points. Antimicrobial resistance was compared 
for weak (n = 47) vs. strong (n = 46) biofilm formation by chi-square or Fisher’s exact test. 
Predictors of strong biofilm formation were identified using logistic regression.
Results. MDR isolates were more common among weak (n  =  46/47, 97.9%) 
vs. strong biofilm formers (n = 35/46, 76.1%; P = 0.002), whereas XDR was similar 
between groups (n = 12/47, 25.5% vs. n = 13/46, 28.3% P = 0.77). Resistance to pen-
icillins, cephalosporins, monobactams, carbapenems, protein synthesis, or fluoro-
quinolones was more common among weak biofilm formers (P < 0.05). Carbapenem 
resistance was inversely associated with strong biofilm formation (odds ratio 0.09; 95% 
confidence interval 0.02–0.33).
Conclusion. Carbapenem-resistant K.  pneumoniae was 91% less likely to form 
strong biofilm. Potential trade-off mechanisms between antimicrobial resistance and 
biofilm formation require further exploration.
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Background. MV is a newly approved β-lactam/β-lactamase inhibitor com-
bination (BLIC) for the treatment of complicated urinary tract infections (cUTI). 
Vaborbactam is a cyclic boronic acid BLI that was mainly developed as a potent inhib-
itor of KPC carbapenemases and other Ambler class A&C enzymes. Vaborbactam 
is inactive against metallo-β-lactamases (MBL) and certain Class D enzymes (e.g. 
OXA-2 and OXA-48). We encountered a case of MV-resistant Klebsiella pneumoniae 
(MVRKP)and sought to explore the various mechanisms of MV resistance within KP.
Methods. A 65-year-old nursing home resident with multiple prior hospitaliza-
tions and recent exposure to antibiotics (Timeline) developed sepsis secondary to car-
bapenem-resistant Klebsiella pneumoniae (CRKP) cUTI. WGS of the patient’s isolate 
was performed. This was followed by random screening for MV resistance and WGS of 
other isolates from a historical database.
Results. Results of WGS are seen in the table below. Sequencing of our patient’s 
isolate revealed strain ST258 with a premature stop in aa89 of OmpK35 as well as inser-
tions at Gly134 and Asp135 (i.e., the GD repeat) of OmpK36. Furthermore, the KPC 
plasmid’s copy number was approximately five times higher than the chromosome. No 
mutations encoding efflux system AcrAB-TolC were found.
Conclusion. Resistance to MV in KP was found in isolates that predate the drug’s 
availability. Notably, resistance occurred in the absence of MBLs and OXAs. The 
mechanism seems to involve outer membrane porin mutations in OmpK35 and/or 
OmpK36. WGS is a useful tool in identifying the mechanism of resistance especially 
for newer agents.
Table: Characterization of MVRKP by WGS









1 2-1-12 16  ST258 KPC-2 & 
SHV-160
Emr, mexk,  
oqxAB, smeD
FS 121insG   S to CZA 
and 
TGC
2 4-3-12 16 ST258 KPC-2 & 
SHV-160
Emr, mexk,  
oqxAB, smeD
FS 121insG   S to CZA 
and 
TGC
3 2013 16 ST258 KPC-2 & 
SHV-160
Emr, mexk,  
oqxAB, smeD
FS 121insG   S to CZA 
and 
TGC
4 2013 4 ST258 KPC-2 & 
SHV-160
Emr, mexk,  
oqxAB, smeD
FS 121insG   S to CZA 
and 
TGC
5 2017  32  ST258 KPC-2, 
SHV-11, 
SHV-12
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